BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up to $4.45

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $4.45, but opened at $5.00. BioCryst Pharmaceuticals shares last traded at $5.35, with a volume of 2,906,898 shares traded.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC restated a “buy” rating and set a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $13.83.

BioCryst Pharmaceuticals Price Performance

The stock has a market capitalization of $1.09 billion, a price-to-earnings ratio of -4.36 and a beta of 1.96. The company has a 50-day simple moving average of $4.93 and a two-hundred day simple moving average of $5.46.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The company had revenue of $93.40 million during the quarter, compared to analyst estimates of $89.19 million. Research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.69 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. increased its stake in BioCryst Pharmaceuticals by 13.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 138,074 shares of the biotechnology company’s stock worth $701,000 after purchasing an additional 15,894 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in BioCryst Pharmaceuticals by 67.3% during the first quarter. China Universal Asset Management Co. Ltd. now owns 39,639 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 15,947 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in BioCryst Pharmaceuticals by 68.0% in the first quarter. Los Angeles Capital Management LLC now owns 89,614 shares of the biotechnology company’s stock worth $455,000 after purchasing an additional 36,284 shares in the last quarter. Vanguard Group Inc. grew its holdings in BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock valued at $106,405,000 after purchasing an additional 2,371,401 shares during the last quarter. Finally, Counterweight Ventures LLC bought a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $81,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.